Drug Trial Radar · NCT07794514
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Apr 1, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; The First Affiliated Hospital of Zhengzhou University; Ruijin Hospital; Tongji Hospital; Peking University People's Hospital; First Affiliated Hospital of Ningbo University
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT. Ruxolitinib and belumosudil are both effective for cGVHD, but no head-to-head comparison specifically in hepatic cGVHD has been reported. Two cohorts are enrolled: Cohort 1 comprises patients with steroid-refractory hepatic cGVHD without prior ruxolitinib or belumosudil exposure, randomized to receive either agent. Cohort 2 includes patients who develop new-onset hepatic cGVHD after ≥4 weeks of therapy with ruxolitinib or belumosudil for other-organ cGVHD (stable for ≥2 weeks), or patients with non-response/progression on either agent for hepatic cGVHD; these patients will be switched to the opposite drug. Key questions include: • In steroid-refractory hepatic cGVHD, does 24-week hepatic overall response rate differ between belumosudil and ruxolitinib? • What is the hepatic response rate after drug switching in Cohort 2? • How do the two agents compare in safety and tolerability for hepatic cGVHD? • What are their impacts on corticosteroid tapering, failure-free survival, and long-term outcomes? Participants will: • Receive assigned treatment per cohort and randomization • Undergo regular efficacy/safety monitoring, including hepatic cGVHD scoring, liver function tests, and adverse event recording • Provide peripheral blood samples at baseline and multiple on-treatment time points for exploratory biomarker analysis • Complete 24-week primary efficacy assessment with follow-up until progression or discontinuation Primary endpoint is 24-week hepatic overall response rate (CR+PR, per 2014 NIH cGVHD criteria). Secondary endpoints include duration of response, failure-free survival, corticosteroid tapering rate, safety (AE/SAE incidence), liver function improvement, and patient-reported outcomes. This head-to-head comparison will provide high-level evidence for selecting second-line and beyond therapies for hepatic cGVHD.
Conditions
- Hematopoietic Stem Cell Transplantation (HSCT)
- cGVHD
- Hepatic cGVHD
- Belumosudil
- Ruxolitinib
Interventions
Ruxolitinib treatmentDrug
Ruxolitinib treatment
Belumosudil treatmentDrug
Belumosudil treatment
Belumosudil Switch to RuxolitinibDrug
Belumosudil Switch to Ruxolitinib
Ruxolitinib Switch to BelumosudilDrug
Ruxolitinib Switch to Belumosudil
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) for Hepatic cGVHD at Week 24Time frame: at Week 24 after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.